| Cat No: | I013055 |
| Cas No: | 320725-47-1 |
| Product-Name: | Squalamine lactate |
| IUPAC Name: | [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-(4-aminobutylamino)propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate;(2S)-2-hydroxypropanoic acid |
| InChI: | InChI=1S/C34H65N3O5S.C3H6O3/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35;1-2(4)3(5)6/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41);2,4H,1H3,(H,5,6)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-;2-/m10/s1 |
| InChIKey: | JMNXSNUXDHHTKQ-QVMSTPCGSA-N |
| SMILES: | CC(C)C(CCC(C)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)NCCCNCCCCN)C)O)C)OS(=O)(=O)O.CC(C(=O)O)O |
Squalamine lactate(cas 320725-47-1) is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
OriginatorGenaera Corporation
DeveloperGenaera Corporation; NeuBase Therapeutics
ClassAntineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
Mechanism of ActionAngiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
Orphan Drug StatusYes - Ovarian cancer
New Molecular EntityYes
[1]. Hussain RM, et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246.
[2]. Emerson MV, et al. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008 Jun;2(2):377-88.
Your information is safe with us.